Hematological Tumor - Pipeline Review, H1 2014

Description: Hematological Tumor - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Hematological Tumor - Pipeline Review, H1 2014’, provides an overview of the Hematological Tumor’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hematological Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematological Tumor and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hematological Tumor
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hematological Tumor and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hematological Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hematological Tumor pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hematological Tumor
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hematological Tumor pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
2
List of Tables 7
List of Figures 10
Introduction 11
REPORT COVERAGE 11
Hematological Tumor Overview 12
Therapeutics Development 13
Pipeline Products for Hematological Tumor - Overview 13
Pipeline Products for Hematological Tumor - Comparative Analysis 14
Hematological Tumor - Therapeutics under Development by Companies 15
Hematological Tumor - Therapeutics under Investigation by Universities/Institutes 22
Hematological Tumor - Pipeline Products Glance 23
Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Hematological Tumor - Products under Development by Companies 26
Hematological Tumor - Products under Investigation by Universities/Institutes 34
Hematological Tumor - Companies Involved in Therapeutics Development 35
F. Hoffmann-La Roche Ltd. 35
AstraZeneca PLC 36
Eli Lilly and Company 37
GlaxoSmithKline plc 38
MedImmune, LLC 39
Gilead Sciences, Inc. 40
Merck & Co., Inc. 41
AbGenomics International, Inc. 42
Dainippon Sumitomo Pharma Co., Ltd. 43
Gamida Cell Ltd. 44
Infinity Pharmaceuticals, Inc. 45
Symphogen A/S 46
Piramal Enterprises Limited 47
Millennium Pharmaceuticals, Inc. 48
Novartis AG 49
Eisai Co., Ltd. 50
Ono Pharmaceutical Co., Ltd. 51
Pfizer Inc. 52
Astex Pharmaceuticals, Inc. 53
Taiho Pharmaceutical Co., Ltd. 54
Celgene Corporation 55
Onyx Pharmaceuticals, Inc. 56
Bayer AG 57
Incyte Corporation 58
4SC AG 59
Basilea Pharmaceutica AG 60
Compugen Ltd. 61
Patrys Limited 62
Curis, Inc. 63
Portola Pharmaceuticals, Inc. 64
Pharmacyclics, Inc. 65
BioInvent International AB 66
Xencor Biosciences plc 67
Threshold Pharmaceuticals, Inc. 68
CrystalGenomics, Inc. 69
Rexahn Pharmaceuticals, Inc. 70
Nerviano Medical Sciences 71
Erytech Pharma SA 72
Aegera Therapeutics Inc. 73
Altor BioScience Corporation 74
Aileron Therapeutics, Inc. 75
Agios Pharmaceuticals, Inc. 76
Arno Therapeutics, Inc. 77
OncoMed Pharmaceuticals, Inc. 78
Constellation Pharmaceuticals, Inc. 79
Bluebird bio, Inc. 80
Stemline Therapeutics, Inc. 81
AndroScience Corporation 82
Fate Therapeutics, Inc. 83
Esperance Pharmaceuticals, Inc. 84
BIND Therapeutics, Inc. 85
Tragara Pharmaceuticals, Inc. 86
Pharma Mar, S.A. 87
Aprea AB 89
arGEN-X BV 90
TRACON Pharmaceuticals, Inc. 91
Merus B.V. 92
Vaxxion Therapeutics, Inc. 93
IkerChem S.L. 94
Immunovative Therapies, Ltd. 95
Targzyme, Inc. 96
Igenica, Inc. 97
Selvita S.A 98
Karyopharm Therapeutics, Inc. 99
Eddingpharm 100
OncoEthix SA 101
Jasco Pharmaceuticals, LLC. 102
Rhizen Pharmaceuticals SA 103
ADC Therapeutics Sarl 104
Ability Pharma, SL 105
Pharmedartis GmbH 106
Oncology Venture ApS 107
Hematological Tumor - Therapeutics Assessment 108
Assessment by Monotherapy Products 108
Assessment by Combination Products 109
Assessment by Target 110
Assessment by Mechanism of Action 115
Assessment by Route of Administration 120
Assessment by Molecule Type 122
Drug Profiles 125
StemEx - Drug Profile 125
alisertib - Drug Profile 127
panobinostat - Drug Profile 130
crizotinib - Drug Profile 136
oprozomib - Drug Profile 139
idelalisib - Drug Profile 141
SL-401 - Drug Profile 143
CG-200745 - Drug Profile 145
APO-010 - Drug Profile 146
Oncohist - Drug Profile 148
MEDI-551 - Drug Profile 150
erismodegib - Drug Profile 152
danusertib - Drug Profile 154
afuresertib - Drug Profile 156
gandotinib - Drug Profile 158
encorafenib - Drug Profile 160
FT-1050 - Drug Profile 161
HSC-835 - Drug Profile 163
abexinostat hydrochloride - Drug Profile 164
ABTL-1014 - Drug Profile 272
ASC-ST.X1 - Drug Profile 273
Monoclonal Antibody Drug Conjugates to Inhibit DNA Synthesis for Solid and Hematological Tumors - Drug Profile 274
ATSP-7041 - Drug Profile 275
RX-0201N - Drug Profile 276
Small Molecule to Inhibit Pim Kinase for Oncology - Drug Profile 277
Small Molecules To Inhibit BET For Cancer - Drug Profile 278
Small Molecules to Inhibit BTK Kinase for Immunology and Oncology - Drug Profile 280
TAS-116 - Drug Profile 281
PAT-NM3 - Drug Profile 282
CLL-05 - Drug Profile 283
BC-2059 - Drug Profile 284
Small Molecules to Inhibit Pan-PIM Kinase for Cancer - Drug Profile 285
BI-1206 - Drug Profile 286
AMP-423 - Drug Profile 287
Monoclonal Antibody for Hematological Tumors - Drug Profile 288
Chimeric Antigen Receptor (CAR) T Cell for Oncology - Drug Profile 289
PMA-406 - Drug Profile 290
ASC-102 - Drug Profile 291
IPI-443 - Drug Profile 292
Small Molecules to Inhibit Kinases for Cancer - Drug Profile 293
VM-101 - Drug Profile 294
Hematologic Tumor Accurin - Drug Profile 295
HCl-1684 - Drug Profile 296
AbGn-122 - Drug Profile 297
LGB-321 - Drug Profile 298
Cell Therapy 2 for Cancer - Drug Profile 299
Cell Therapy 3 for Cancer - Drug Profile 300
Cell Therapy 4 for Cancer - Drug Profile 301
Small Molecules to Inhibit DNMT for Solid Tumor and Hematological Tumor - Drug Profile 302
Small Molecules to Inhibit JMj for Solid Tumor and Hematological Tumor - Drug Profile 303
Small Molecules to Inhibit AXL Kinase for Hematological Tumor - Drug Profile 304
Small Molecules to Inhibit Proteasome for Solid Tumor and Hematological Tumor - Drug Profile 305
Monoclonal Antibody Targeting CGEN-15001T for Cancer - Drug Profile 306
Small Molecules for Hematological and Solid Cancers - Drug Profile 307
Small Molecule to Inhibit Hedgehog for Cancer - Drug Profile 308
APR-246 Analogues - Drug Profile 309
Small Molecule to Inhibit BTK for Cancer - Drug Profile 310
Small Molecule to Inhibit Casein Kinase 1 for Cancer - Drug Profile 311
Small Molecules to Inhibit HDAC-2 for Oncology And Central Nervous System Disorders - Drug Profile 312
Ubiquitin Proteasome System Inhibitors - Drug Profile 313
Drugs to Inhibit Integrin Beta1 For Hematological Tumors - Drug Profile 314
Perk Kinase Inhibitor - Drug Profile 315
Sym-012 - Drug Profile 316
Thorium-Anti CD22 Monoclonal Antibody - Drug Profile 317
Small Molecule for Hematologic Malignancies - Drug Profile 318
Monoclonal Antibodies for Blood Cancers - Drug Profile 319
SEL-201 - Drug Profile 320
SEL-300 - Drug Profile 321
Small Molecules to Inhibit Kinase for Cancer - Drug Profile 322
Drugs to Inhibit DNA Methyl Transferase for Hematological Cancers - Drug Profile 323
Hematological Tumor - Recent Pipeline Updates 324
Hematological Tumor - Dormant Projects 426
Hematological Tumor - Discontinued Products 430
Hematological Tumor - Product Development Milestones 431
Featured News & Press Releases 431
Appendix 440
Methodology 440
Coverage 440
Secondary Research 440
Primary Research 440
Expert Panel Validation 440
## List of Tables

<table>
<thead>
<tr>
<th>Table Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Products under Development for Hematological Tumor, H1 2014</td>
<td>22</td>
</tr>
<tr>
<td>Number of Products under Development for Hematological Tumor - Comparative Analysis, H1 2014</td>
<td>23</td>
</tr>
<tr>
<td>Number of Products under Development by Companies, H1 2014</td>
<td>25</td>
</tr>
<tr>
<td>Number of Products under Development by Companies, H1 2014 (Contd..1)</td>
<td>26</td>
</tr>
<tr>
<td>Number of Products under Development by Companies, H1 2014 (Contd..2)</td>
<td>27</td>
</tr>
<tr>
<td>Number of Products under Development by Companies, H1 2014 (Contd..3)</td>
<td>28</td>
</tr>
<tr>
<td>Number of Products under Development by Companies, H1 2014 (Contd..4)</td>
<td>29</td>
</tr>
<tr>
<td>Number of Products under Development by Companies, H1 2014 (Contd..5)</td>
<td>30</td>
</tr>
<tr>
<td>Number of Products under Investigation by Universities/Institutes, H1 2014</td>
<td>31</td>
</tr>
<tr>
<td>Comparative Analysis by Late Stage Development, H1 2014</td>
<td>32</td>
</tr>
<tr>
<td>Comparative Analysis by Clinical Stage Development, H1 2014</td>
<td>33</td>
</tr>
<tr>
<td>Comparative Analysis by Early Stage Development, H1 2014</td>
<td>34</td>
</tr>
<tr>
<td>Products under Development by Companies, H1 2014</td>
<td>35</td>
</tr>
<tr>
<td>Products under Development by Companies, H1 2014 (Contd..1)</td>
<td>36</td>
</tr>
<tr>
<td>Products under Development by Companies, H1 2014 (Contd..2)</td>
<td>37</td>
</tr>
<tr>
<td>Products under Development by Companies, H1 2014 (Contd..3)</td>
<td>38</td>
</tr>
<tr>
<td>Products under Development by Companies, H1 2014 (Contd..4)</td>
<td>39</td>
</tr>
<tr>
<td>Products under Development by Companies, H1 2014 (Contd..5)</td>
<td>40</td>
</tr>
<tr>
<td>Products under Development by Companies, H1 2014 (Contd..6)</td>
<td>41</td>
</tr>
<tr>
<td>Products under Development by Companies, H1 2014 (Contd..7)</td>
<td>42</td>
</tr>
<tr>
<td>Products under Investigation by Universities/Institutes, H1 2014</td>
<td>43</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014</td>
<td>44</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by AstraZeneca PLC, H1 2014</td>
<td>45</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Eli Lilly and Company, H1 2014</td>
<td>46</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by GlaxoSmithKline plc, H1 2014</td>
<td>47</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by MedImmune, LLC, H1 2014</td>
<td>48</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Gilead Sciences, Inc., H1 2014</td>
<td>49</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Merck &amp; Co., Inc., H1 2014</td>
<td>50</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by AbGenomics International, Inc., H1 2014</td>
<td>51</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014</td>
<td>52</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Gamida Cell Ltd., H1 2014</td>
<td>53</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014</td>
<td>54</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Symphogen A/S, H1 2014</td>
<td>55</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Piramal Enterprises Limited, H1 2014</td>
<td>56</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014</td>
<td>57</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Novartis AG, H1 2014</td>
<td>58</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Eisai Co., Ltd., H1 2014</td>
<td>59</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014</td>
<td>60</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Pfizer Inc., H1 2014</td>
<td>61</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Astex Pharmaceuticals, Inc., H1 2014</td>
<td>62</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014</td>
<td>63</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Celgene Corporation, H1 2014</td>
<td>64</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014</td>
<td>65</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Bayer AG, H1 2014</td>
<td>66</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Incyte Corporation, H1 2014</td>
<td>67</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by 4SC AG, H1 2014</td>
<td>68</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Basilea Pharmaceutica AG, H1 2014</td>
<td>69</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Compugen Ltd., H1 2014</td>
<td>70</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Patrys Limited, H1 2014</td>
<td>71</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Curis, Inc., H1 2014</td>
<td>72</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Portola Pharmaceuticals, Inc., H1 2014</td>
<td>73</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Pharmacyclics, Inc., H1 2014</td>
<td>74</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by BiolVent International AB, H1 2014</td>
<td>75</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Xenetic Biosciences plc, H1 2014</td>
<td>76</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014</td>
<td>77</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by CrystalGenomics, Inc., H1 2014</td>
<td>78</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2014</td>
<td>79</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Nerviano Medical Sciences, H1 2014</td>
<td>80</td>
</tr>
<tr>
<td>Hematological Tumor - Pipeline by Erytech Pharma SA, H1 2014</td>
<td>81</td>
</tr>
</tbody>
</table>
Hematological Tumor - Pipeline by Aegera Therapeutics Inc., H1 2014 82
Hematological Tumor - Pipeline by Altor BioScience Corporation, H1 2014 83
Hematological Tumor - Pipeline by Aileron Therapeutics, Inc., H1 2014 84
Hematological Tumor - Pipeline by Agios Pharmaceuticals, Inc., H1 2014 85
Hematological Tumor - Pipeline by Arno Therapeutics, Inc., H1 2014 86
Hematological Tumor - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2014 87
Hematological Tumor - Pipeline by Constellation Pharmaceuticals, Inc., H1 2014 88
Hematological Tumor - Pipeline by Bluebird bio, Inc., H1 2014 89
Hematological Tumor - Pipeline by Stemline Therapeutics, Inc., H1 2014 90
Hematological Tumor - Pipeline by AndroScience Corporation, H1 2014 91
Hematological Tumor - Pipeline by Fate Therapeutics, Inc., H1 2014 92
Hematological Tumor - Pipeline by Esperance Pharmaceuticals, Inc., H1 2014 93
Hematological Tumor - Pipeline by BIND Therapeutics, Inc., H1 2014 94
Hematological Tumor - Pipeline by Tragara Pharmaceuticals, Inc., H1 2014 95
Hematological Tumor - Pipeline by Pharma Mar, S.A., H1 2014 96
Hematological Tumor - Pipeline by AmplitMed Corporation, H1 2014 97
Hematological Tumor - Pipeline by Aprea AB, H1 2014 98
Hematological Tumor - Pipeline by AndroScience Corporation, H1 2014 99
Hematological Tumor - Pipeline by TRACON Pharmaceuticals, Inc., H1 2014 100
Hematological Tumor - Pipeline by Merus B.V., H1 2014 101
Hematological Tumor - Pipeline by Vaxion Therapeutics, Inc., H1 2014 102
Hematological Tumor - Pipeline by IkerChem S.L., H1 2014 103
Hematological Tumor - Pipeline by Immunovative Therapies, Ltd., H1 2014 104
Hematological Tumor - Pipeline by Targazyme, Inc., H1 2014 105
Hematological Tumor - Pipeline by Igenica, Inc., H1 2014 106
Hematological Tumor - Pipeline by Selvita S.A, H1 2014 107
Hematological Tumor - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 108
Hematological Tumor - Pipeline by Eddingpharm, H1 2014 109
Hematological Tumor - Pipeline by OncoEthix SA, H1 2014 110
Hematological Tumor - Pipeline by Jasco Pharmaceuticals, LLC., H1 2014 111
Hematological Tumor - Pipeline by Rhizen Pharmaceuticals SA, H1 2014 112
Hematological Tumor - Pipeline by ADC Therapeutics Sarl, H1 2014 113
Hematological Tumor - Pipeline by Ability Pharma, SL, H1 2014 114
Hematological Tumor - Pipeline by Pharmadartis GmbH, H1 2014 115
Hematological Tumor - Pipeline by Oncology Venture ApS, H1 2014 116
Assessment by Monotherapy Products, H1 2014 117
Assessment by Combination Products, H1 2014 118
Number of Products by Stage and Target, H1 2014 121
Number of Products by Stage and Mechanism of Action, H1 2014 126
Number of Products by Stage and Route of Administration, H1 2014 130
Number of Products by Stage and Molecule Type, H1 2014 133
Hematological Tumor Therapeutics - Recent Pipeline Updates, H1 2014 333
Hematological Tumor - Dormant Projects, H1 2014 435
Hematological Tumor - Dormant Projects (Contd..1), H1 2014 436
Hematological Tumor - Dormant Projects (Contd..2), H1 2014 437
Hematological Tumor - Dormant Projects (Contd..3), H1 2014 438
Hematological Tumor - Discontinued Products, H1 2014 439

List of Figures
Number of Products under Development for Hematological Tumor, H1 2014 22
Number of Products under Development for Hematological Tumor - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 24
Number of Products under Investigation by Universities/Institutes, H1 2014 31
Comparative Analysis by Clinical Stage Development, H1 2014 33
Comparative Analysis by Early Stage Products, H1 2014 34
Assessment by Monotherapy Products, H1 2014 117
Number of Products by Top 10 Target, H1 2014 119
Number of Products by Stage and Top 10 Target, H1 2014 120
Number of Products by Top 10 Mechanism of Action, H1 2014 124
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 125
Number of Products by Top 10 Route of Administration, H1 2014 129
Number of Products by Stage and Top 10 Route of Administration, H1 2014 130
Number of Products by Top 10 Molecule Type, H1 2014 131
Number of Products by Stage and Top 10 Molecule Type, H1 2014 132

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: Hematological Tumor - Pipeline Review, H1 2014
- Web Address: http://www.researchandmarkets.com/reports/2882206/
- Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

- Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
- First Name: __________________________ Last Name: __________________________
- Email Address: * __________________________
- Job Title: __________________________
- Organisation: __________________________
- Address: __________________________
- City: __________________________
- Postal / Zip Code: __________________________
- Country: __________________________
- Phone Number: __________________________
- Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World